For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The purpose of this study is to test the good and bad effects of a combination of new drugs on you and your advanced ovarian cancer for which platinum based chemotherapy is no longer an option.
The purpose of this study is to evaluate if specific testing of vulva cancer tissue that is removed by surgery provides useful information to help decide if additional surgery is required or not.
The usual approach to treating early-stage vulvar cancer consists of a single surgery to remove the cancer.
The purpose of this study is to compare the effects on you and your endometrial cancer of a new drug in combination with radiation therapy compared to the current standard treatment of radiation therapy alone.
The purpose of this study is to identify people who may not require treatment after surgery or may require less treatment after surgery because their cancer is at such a low risk of coming back based on the specific tumour features found by the laboratory testing and the extent of tumour spread. Receiving no treatment or less treatment can result in no or fewer side effects (fatigue, hair loss, bowel and bladder irritation).
